Clinical Competition Candidate
NAMZARIC
NAMZARIC carries use-code patent, moderate complexity (2/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 41 months away. Active clinical competition may compress the generic entry window.
LOE window
41months
to latest listed patent expiry (December 5, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 3
Complexity score: 2/5
Clinical competition
Score: 4/5
Active trials linked: 52
Phase 2/3 trials: 12
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE
Applicant (NDA holder): ABBVIE INC
Confidence: Medium